Search Result

Isoforms Recommended:	COX-1

Results for "

human COX-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	COX (61) Akt (4) Apoptosis (24) Autophagy (3) Bacterial (5) Collagen (1) Cytochrome P450 (1) Elastase (1) Environmental Pollutants (2) ERK (3) Estrogen Receptor/ERR (1) IKK (4) Influenza Virus (1) Interleukin Related (2) Isotope-Labeled Compounds (13) JNK (2) Keap1-Nrf2 (2) Lipoxygenase (3) NF-κB (8) NO Synthase (2) p38 MAPK (3) PGE synthase (6) Prostaglandin Receptor (1) RANKL/RANK (2) Reference Standards (15) SARS-CoV (1) Sirtuin (1) TNF Receptor (3)
By Research Areas:	Cancer (40) Cardiovascular Disease (1) Infection (5) Inflammation/Immunology (58) Metabolic Disease (1) Neurological Disease (6)

By Targets:

COX (61)

Akt (4)

Apoptosis (24)

Autophagy (3)

Bacterial (5)

Collagen (1)

Cytochrome P450 (1)

Elastase (1)

Environmental Pollutants (2)

ERK (3)

Estrogen Receptor/ERR (1)

IKK (4)

Influenza Virus (1)

Interleukin Related (2)

Isotope-Labeled Compounds (13)

JNK (2)

Keap1-Nrf2 (2)

Lipoxygenase (3)

NF-κB (8)

NO Synthase (2)

p38 MAPK (3)

PGE synthase (6)

Prostaglandin Receptor (1)

RANKL/RANK (2)

Reference Standards (15)

SARS-CoV (1)

Sirtuin (1)

TNF Receptor (3)

By Research Areas:

Cancer (40)

Cardiovascular Disease (1)

Infection (5)

Inflammation/Immunology (58)

Metabolic Disease (1)

Neurological Disease (6)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Antibodies

Targets Recommended: COX

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15036

Diclofenac Maximum Cited Publications 24 Publications Verification	COX Apoptosis	Inflammation/Immunology Cancer
Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a *COX* inhibitor, with IC₅₀s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .

HY-B0253

Piroxicam 4 Publications Verification CP-16171	COX	Inflammation/Immunology Cancer
Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a *COX* inhibitor, with IC₅₀s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively.

HY-111310

ML351 2 Publications Verification	Lipoxygenase	Neurological Disease Metabolic Disease
ML351 is a potent and highly specific 15-LOX-1 inhibitor with an IC₅₀ of 200 nM. ML351 shows excellent selectivity (>250-fold) versus the related isozymes, 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2 . ML351 prevents dysglycemia and reduces β-cell oxidative stress in nonobese diabetic mouse model of T1D .

HY-15038

Diclofenac potassium Maximum Cited Publications 24 Publications Verification	COX Apoptosis	Inflammation/Immunology Cancer
Diclofenac potassium is a potent and nonselective anti-inflammatory agent, acts as a *COX* inhibitor, with IC₅₀s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac potassium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .

HY-17372

Rofecoxib 5 Publications Verification MK 966	COX	Inflammation/Immunology Cancer
Rofecoxib is a potent, specific and orally active *COX-2* inhibitor, with IC₅₀s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC₅₀ > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells).

HY-B0808

Oxaprozin Oxaprozinum; Wy21743	COX NF-κB Akt IKK Apoptosis	Inflammation/Immunology Cancer
Oxaprozin is an orally active and potent *COX* inhibitor, with IC₅₀ values of 2.2 μM for human platelet *COX-1* and and 36 μM for IL-1-stimulated human synovial cell *COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. Oxaprozin induces cell apoptosis. Oxaprozin shows anti-inflammatory activity. Oxaprozin-mediated inhibition of the Akt/IKK/NF-κB* pathway contributes to its anti-inflammatory properties .

HY-N0481

Roburic acid 1 Publications Verification	COX TNF Receptor NO Synthase Interleukin Related NF-κB Apoptosis p38 MAPK JNK ERK Keap1-Nrf2 RANKL/RANK	Neurological Disease Inflammation/Immunology Cancer
Roburic acid acts as an anti-inflammatory, anti-tumor and osteoclastogenesis inhibitor, with a K_i of 7.066 μM against human TNF, an IC₅₀ of 9 μM against human *COX-2, and an IC₅₀* of 5 μM against ovine *COX-1. Roburic acid reduces the production of inflammatory mediators such as NO and IL-6* in macrophages by inhibiting the NF-κB and MAPK (p38/JNK) pathways. By competitively inhibiting the TNF-TNF-R1 interaction, Roburic acid blocks the downstream NF-κB signaling pathway, thereby inducing cell cycle arrest and apoptosis in cancer cells. Roburic acid specifically inhibits osteoclastogenesis and bone resorption by suppressing the RANKL/TRAF6/NF-κB/NFATc1 axis. Roburic acid can be used in research related to osteolytic diseases such as osteoporosis, colorectal cancer and inflammatory diseases .

HY-15037

Diclofenac Sodium Maximum Cited Publications 24 Publications Verification GP 45840	COX Apoptosis	Inflammation/Immunology Cancer
Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a *COX* inhibitor, with IC₅₀s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .

HY-15321

Etoricoxib MK-0663; L-791456	COX	Inflammation/Immunology Cancer
Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active *COX-2* inhibitor. Etoricoxib can cross the blood-brain barrier, with IC₅₀s of 1.1 μM and 116 μM for *COX-2* and *COX-1* in human whole blood .

HY-15036A

Diclofenac diethylamine Maximum Cited Publications 24 Publications Verification	COX Apoptosis	Inflammation/Immunology Cancer
Diclofenac diethylamine is a potent and nonselective anti-inflammatory agent, acts as a *COX* inhibitor, with IC₅₀s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac diethylamine induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .

HY-15036S

Diclofenac-d4	Isotope-Labeled Compounds COX Apoptosis	Inflammation/Immunology
Diclofenac-d₄ is the deuterium labeled Diclofenac. Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC₅₀s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .

HY-B1799

Tolmetin 1 Publications Verification	COX	Inflammation/Immunology Cancer
Tolmetin is an orally active and potent *COX* inhibitor with IC₅₀s of 0.35 μM and 0.82 μM human COX-1 and COX-2, respectively. Tolmetin is a non-steroidal anti-inflammatory drug (NSAID) .

HY-W012817

Methylhydroquinone	Environmental Pollutants COX	Inflammation/Immunology
Methylhydroquinone is an orally active *COX* inhibitor with IC₅₀s of 480.7 μM and 52.2 μM for ovine COX-1 and human recombinant COX-2, respectively. Methylhydroquinone has potential DNA damaging effects: 1) inhibiting COX-1 to reduce prostaglandin synthesis and exert anti-inflammatory activity; 2) inducing DNA single-strand breaks. Methylhydroquinone exerts its effects by competitively binding to the active sites of COX-1 (such as Tyr385, Met522) and non-covalent interactions .

HY-15037R

Diclofenac Sodium (Standard) GP 45840 (Standard)	Reference Standards COX Apoptosis	Inflammation/Immunology Cancer
Diclofenac (Sodium) (Standard) is the analytical standard of Diclofenac (Sodium). This product is intended for research and analytical applications. Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a *COX* inhibitor, with IC₅₀s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .

HY-10439

HPGDS inhibitor 1	PGE synthase	Inflammation/Immunology
HPGDS inhibitor 1 is a potent, selective and orally active Hematopoietic Prostaglandin D Synthase (HPGDS) inhibitor with an IC₅₀s of 0.6 nM and 32 nM in enzyme and cellular assays, respectively. HPGDS inhibitor 1 does not inhibit human L-PGDS, mPGES, COX-1, COX-2, or 5-LOX .

HY-14837

Amizon Enisamium iodide	Influenza Virus SARS-CoV	Infection
Amizon is an orally effective antiviral and anti-inflammatory agent. Amizon inhibits influenza virus replication and restricts viral RNA synthesis. Amizon reduces the mRNA expression of COX-1, COX-2, NF-κB, TGF1β, IL-1 and IL-6, and stimulates the secretion and mRNA expression of IL-10. Amizon inhibits the oxidative activity of macrophages and possesses antioxidant and free radical-scavenging activities. Amizon is applicable to research related to influenza and acute respiratory viral infections .

HY-B2218D

Magnesium hydroxide, 99%(KT) Magnesium dihydroxide, 99%(KT)	Environmental Pollutants Bacterial	Infection Inflammation/Immunology
Magnesium hydroxide (Magnesium dihydroxide), 99%(KT) is an orally effective antacid. Magnesium hydroxide, 99%(KT) can form a local strongly alkaline microenvironment, reduce ATP production by consuming H ⁺, and hydrolyze cellular phospholipids to disrupt the cellular integrity of microorganisms, thus exhibiting antibacterial activity. Magnesium hydroxide, 99%(KT) downregulates the generation of inflammatory macrophages to alleviate inflammatory responses. Magnesium hydroxide, 99%(KT) can be used in research related to acid peptic diseases and chronic wound infections .

HY-108259

HQL-79	PGE synthase	Inflammation/Immunology
HQL-79, a potent, selective and orally active human hematopoietic prostaglandin D synthase (H-PGDS) inhibitor, highly selectively inhibits the synthesis of PGD₂, and acts as an anti-allergic agent, with a K_d of 0.8 μM and an IC₅₀ of 6 μM. Shows no obvious effect on COX-1, COX-2, m-PGES, or L-PGDS .

HY-139589

Zaloglanstat ISC-27864; GRC-27864	PGE synthase COX Collagen	Neurological Disease Inflammation/Immunology
Zaloglanstat (ISC-27864; GRC-27864) is a selective, orally active microsomal mPGES-1 inhibitor. Zaloglanstat has an IC₅₀ of 5 nM for human mPGES-1 without significant inhibitory effect on COX-1/2 (IC₅₀ >10 μM). Zaloglanstat blocks the conversion of arachidonic acid metabolite prostaglandin PGH₂ to prostaglandin PGE₂, thereby inhibiting inflammation-related PGE₂ overproduction and reducing inflammatory responses and pain. Zaloglanstat inhibits IL-1β-induced PGE₂ release in A549 cells and human synovial fibroblasts in vitro. Zaloglanstat inhibits PGE2 release in pig and dog whole blood with IC₅₀s ??of 161 nM and 154 nM, respectively. Zaloglanstat can be used in the study of asthma, osteoarthritis, and neurodegenerative diseases .

HY-15036R

Diclofenac (Standard)	Reference Standards COX Apoptosis	Inflammation/Immunology Cancer
Diclofenac (Standard) is the analytical standard of Diclofenac. This product is intended for research and analytical applications. Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .

HY-103387

DuP-697 1 Publications Verification	COX Apoptosis	Inflammation/Immunology Cancer
DuP-697 is a member of the vicinal diaryl heterocycles and a potent, irreversible, selective and orally active *COX-2* inhibitor (IC₅₀ of 10 nM and 800 nM for human *COX-2* and *COX-1, respectively). DuP-697 exerts antiproliferative (IC₅₀* of 42.8 nM), antiangiogenic and apoptotic effects on HT29 colorectal cancer cells. DuP-697 inhibits prostaglandin synthesis and has anti-inflammatory, anticancer and antipyretic effects .

HY-15036S1

Diclofenac-13C6	Isotope-Labeled Compounds COX Apoptosis	Inflammation/Immunology
Diclofenac- ¹³C₆ is the ¹³C₆ labeled Diclofenac. Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade.

HY-B1489

Tolmetin sodium dihydrate 1 Publications Verification	COX	Inflammation/Immunology Cancer
Tolmetin sodium dihydrate is an orally active and potent *COX* inhibitor with IC₅₀s of 0.35 μM and 0.82 μM human COX-1 and COX-2, respectively. Tolmetin sodium dihydrate is a non-steroidal anti-inflammatory drug (NSAID) .

HY-W012126

2,6-Dichlorodiphenylamine 2,6-Dichloro-N-phenylaniline	Bacterial	Infection Cancer
2,6-Dichlorodiphenylamine is an analogue of Diclofenac Sodium (HY-15037) and has anti-Candida albicans activity. Diclofenac Sodium is a potent and nonselective anti-inflammatory agent, acts as a COX* inhibitor,* with IC₅₀s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells.

HY-15321S

Etoricoxib-d4 1 Publications Verification MK-0663-d₄; L-791456-d₄	COX	Others
Etoricoxib-d₄ (MK-0663-d₄) is a deuterium labeled Etoricoxib. Etoricoxib is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.

HY-15037S2

Diclofenac-13C6 sodium GP 45840-¹³C₆	Isotope-Labeled Compounds COX Apoptosis	Inflammation/Immunology
Diclofenac- ¹³C₆ (Sodium) is the ¹³C₆ labeled Diclofenac (Sodium). Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade.

HY-15037S1

Diclofenac-d4 sodium	COX Apoptosis	Inflammation/Immunology
Diclofenac-d₄ (sodium) is the deuterium labeled Diclofenac sodium. Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC₅₀s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .

HY-B0227S

Ketoprofen-d3 RP-19583-d₃	COX Apoptosis	Inflammation/Immunology
Ketoprofen-d₃ is the deuterium labeled Ketoprofen. Ketoprofen (RP-19583) is a non-steroidal antiinflammatory agent, acting as a potent inhibitor of COX, with IC₅₀s of 2 nM and 26 nM for COX-1 and COX-2 in human blood monocytes, respectively .

HY-14397S

Indomethacin-d4 Indometacin-d₄	Isotope-Labeled Compounds COX Autophagy	Inflammation/Immunology Cancer
Indomethacin-d₄ (Indometacin-d₄) is a deuterium labeled Indomethacin. Indomethacin is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2, with IC₅₀s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells . Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes .

HY-19212

S-2474	COX Lipoxygenase	Inflammation/Immunology
S-2474 is an inhibitor of *COX-2* and 5-lipoxygenase (5-LO), with IC₅₀s of 11 nM and 27 μM for COX-2 and COX-1 in human intact cells, and used as a nonsteroidal anti-inflammatory agent.

HY-B0253R

Piroxicam (Standard) CP-16171 (Standard)	Reference Standards COX	Inflammation/Immunology Cancer
Piroxicam (Standard) is the analytical standard of Piroxicam. This product is intended for research and analytical applications. Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively.

HY-123823

Nitroaspirin NCX 4016	COX Apoptosis	Cancer
Nitroaspirin (NCX 4016) is a nitric oxide (NO) donor and a nitro-derivative of Aspirin, which combines with Nitroaspirin to inhibit cyclooxygenase. Nitroaspirin (NCX 4016) has antithrombotic and anti-platelet properties and acts as a direct and irreversible inhibitor of *COX-1. Nitroaspirin (NCX 4016) causes significant induction of cell cycle arrest and apoptosis* in Cisplatin-resistant human ovarian cancer cells via down-regulation of EGFR/PI3K/STAT3 signaling and modulation of Bcl-2 family proteins .

HY-100516

Cimicoxib UR-8880	COX Cytochrome P450	Inflammation/Immunology
Cimicoxib (UR-8880) is an orally active, blood-brain barrier-permeable COX-2 inhibitor that also exerts targeted inhibition on CYP2D15. It has an IC₅₀ of 66 nM against hCOX-2, an IC₅₀ of 1.6 μM against canine CYP2D15, and an IC₅₀ of 0.056 μM against feline CYP2D15. By inhibiting the COX-2 pathway to reduce the production of thromboxane B2 and prostaglandin E2, Cimicoxib exerts antipyretic, anti-inflammatory and analgesic effects. Cimicoxib is metabolized by CYP2D15 to form demethyl-cimicoxib, undergoes glucuronidation via UDP-glucuronosyltransferases, and exhibits biphasic elimination kinetics in beagle dogs. Cimicoxib is widely used in studies of inflammatory diseases, osteoarthritis, and perioperative pain associated with orthopedic or soft tissue surgeries .

HY-169430

AGU654	PGE synthase
AGU654 (Compound 44) is a selective mPGES-1 inhibitor with an IC₅₀ of 2.9 nM against mPGES-1. AGU654 inhibits mPGES-1 to block the pathway converting arachidonic acid into prostaglandin E2 (PGE2) by *COX-1/2, thereby alleviating inflammatory responses, pain, and fever. In activated human* monocyte-derived macrophages and human whole blood models, AGU654 selectively suppresses bacterial exotoxin-induced PGE2 production while preserving the production of other prostaglandins. In guinea pig models, AGU654 significantly alleviates fever, inflammation, and inflammatory pain, exhibiting excellent anti-inflammatory, analgesic, and antipyretic effects. AGU654 holds promise as a strategy for studying inflammatory diseases and pain .

HY-111274

Indomethacin farnesil Indometacin farnesil	COX Autophagy	Inflammation/Immunology
Indomethacin farnesil is an orally active proagent of Indomethacin. Indomethacin (Indometacin) is a potent, blood-brain permeable and nonselective inhibitor of *COX1* and *COX2, with IC₅₀s* of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells. Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes .

HY-14397S1

Indomethacin-d4 Methyl Ester	COX Autophagy	Inflammation/Immunology Cancer
Indomethacin-d₄ Methyl Ester is the deuterium labeled Indomethacin. Indomethacin (Indometacin) is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2, with IC₅₀s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells . Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes .

HY-15038R

Diclofenac potassium (Standard)	Reference Standards COX Apoptosis	Inflammation/Immunology Cancer
Diclofenac (potassium) (Standard) is the analytical standard of Diclofenac (potassium). This product is intended for research and analytical applications. Diclofenac potassium is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC₅₀s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac potassium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .

HY-15036AR

Diclofenac diethylamine (Standard)	Reference Standards COX Apoptosis	Inflammation/Immunology Cancer
Diclofenac (diethylamine) (Standard) is the analytical standard of Diclofenac (diethylamine). This product is intended for research and analytical applications. Diclofenac diethylamine is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac diethylamine induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .

HY-B0253S

Piroxicam-d3 CP-16171 d₃	COX	Inflammation/Immunology Cancer
Piroxicam-d₃ (CP-16171-d₃) is deuterium labeled Piroxicam. Piroxicam is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC₅₀s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively .

HY-15321R

Etoricoxib (Standard) MK-0663 (Standard); L-791456 (Standard)	Reference Standards COX	Inflammation/Immunology Cancer
Etoricoxib (Standard) is the analytical standard of Etoricoxib. This product is intended for research and analytical applications. Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active *COX-2* inhibitor, with IC₅₀s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.

HY-15321S2

Etoricoxib-d3 MK-0663-d₃; L-791456-d₃	COX	Inflammation/Immunology
Etoricoxib-d₃ is the deuterium labeled Etoricoxib . Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC₅₀s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood .

HY-17372S

Rofecoxib-d5	Isotope-Labeled Compounds COX	Inflammation/Immunology Cancer
Rofecoxib-d₅ is the deuterium labeled Rofecoxib. Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC₅₀s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC₅₀ > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells) .

HY-N10009

Cudraflavone B	NF-κB TNF Receptor COX ERK p38 MAPK Sirtuin	Inflammation/Immunology
Cudraflavone B is a prenylated flavonoid with anti-inflammatory and anti-tumor properties. Cudraflavone B is also a dual inhibitor of *COX-1* and *COX-2. Cudraflavone B blocks the translocation of nuclear factor κB* (NF-κB) from the cytoplasm to the nucleus in macrophages. Thus, Cudraflavone B inhibits tumor necrosis factor α (TNFα) gene expression and secretion. Cudraflavone B also triggers the mitochondrial apoptotic pathway, activates NF-κB, the MAPK p38, and ERK, and induced the expression of SIRT1. Thus Cudraflavone B inhibits the growth of human oral squamous cell carcinoma cells .

HY-165587

BM-573	Prostaglandin Receptor	Cardiovascular Disease
BM-573 is an orally active dual thromboxane A₂ (TXA₂) modulator with an IC₅₀ of 1.3 nM. BM-573 possesses both thromboxane synthase (TxAS) inhibition and thromboxane receptor (TP) antagonistic effects. BM-573 can completely inhibit platelet aggregation induced by Arachidonic acid (HY-109590) or U-46619 (TXA₂ analogues). BM-573 completely blocks the generation of TXB₂ (the stable metabolite of TXA₂) in human platelets and does not inhibit cyclooxygenase (COX-1/COX-2), thus avoiding interference with other prostaglandin synthesis. BM-573 has an inhibitory effect on U-46619-induced contractions in rat gastric fundus smooth muscle (ED₅₀ = 4.2 μM), but has no effect on contractions caused by PGE₂, PGF₂α, or PGI₂. BM-573 can be used in the study of atherosclerosis, myocardial infarction, pulmonary hypertension and shock .

HY-B0808S1

Oxaprozin-d5 Oxaprozinum-d₅; Wy21743-d₅	Isotope-Labeled Compounds COX NF-κB	Inflammation/Immunology Cancer
Oxaprozin-d₅ is deuterium labeled Oxaprozin. Oxaprozin is an inhibitor of both COX-1 and COX-2 with IC50s of 2.2 μM and 36 μM for human platelet COX-1 and IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB.

HY-W012817R

Methylhydroquinone (Standard)	COX Reference Standards	Others
Methylhydroquinone (Standard) is the analytical standard of Methylhydroquinone. This product is intended for research and analytical applications. Methylhydroquinone is an orally active COX inhibitor with IC50s of 480.7 μM and 52.2 μM for ovine COX-1 and human recombinant COX-2, respectively. Methylhydroquinone has potential DNA damaging effects: 1) inhibiting COX-1 to reduce prostaglandin synthesis and exert anti-inflammatory activity; 2) inducing DNA single-strand breaks. Methylhydroquinone exerts its effects by competitively binding to the active sites of COX-1 (such as Tyr385, Met522) and non-covalent interactions[1][2].

HY-135081

N-(4-acetamidophenyl)-Indomethacin amide N-4AIA	COX	Others
N-(4-acetamidophenyl)-indomethacin amide (N-4-AIA) is one of several aromatic amides of indomethacin reported to be potent and selective reversible inhibitors of COX-2.1 N-4-AIA inhibits human recombinant and ovine COX-2 with IC₅₀ values of 0.12 and 0.625 μM, respectively. It is about 400 times less potent as an inhibitor of human recombinant COX-1 and 80 times less potent as an inhibitor of ovine COX-1 than ovine COX-2.

HY-106093

Eltenac	COX	Inflammation/Immunology
Eltenac, a non-steroidal anti-inflammatory drug (NSAID), is a COX inhibitor. Eltenac shows IC50 of 0.03 μM for both COX-1 and COX-2 in isolated human whole blood .

HY-15037S

Diclofenac-13C6 sodium heminonahydrate	Isotope-Labeled Compounds COX Apoptosis	Inflammation/Immunology
Diclofenac- ¹³C₆ (sodium heminonahydrate) is the ¹³C-labeled Diclofenac Sodium. Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC₅₀s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .

HY-B0253A

Piroxicam olamine CP-16171 olamine	COX	Inflammation/Immunology Cancer
Piroxicam olamine (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a *COX* inhibitor, with IC₅₀s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively .

Cat. No.	Product Name

HY-L914

Serine/Threonine Focused Covalent Fragment Library

3,208 compounds

In the research of covalent inhibitors targeting serine and threonine, scientists have found that the nucleophilicity of these hydroxyl groups is significantly enhanced due to the influence of their surrounding environment. This results in higher activity during catalytic reactions. Aspirin, which targets the non-catalytic domain serine (Ser529 in human COX1) of cyclooxygenase, exerts its anti-inflammatory effect through covalent binding. β-lactam antibiotics, which targets the catalytic domain serine of penicillin-binding proteins, interferes with bacterial cell wall synthesis.

Through careful selection, we constructed a structural filter containing over 110 electrophilic groups. By analyzing the electrophilic fragments selected by the structural filter, we removed any molecules with trivial or undesirable structural features. Ultimately, we obtained 3,300 fragment molecules which can target serine and threonine residues and can be used for fragment-based covalent drug discovery.

Cat. No.	Product Name	Type

HY-B2218D

Magnesium hydroxide, 99%(KT)

Magnesium dihydroxide, 99%(KT)

Biochemical Assay Reagents

Magnesium hydroxide (Magnesium dihydroxide), 99%(KT) is an orally effective antacid. Magnesium hydroxide, 99%(KT) can form a local strongly alkaline microenvironment, reduce ATP production by consuming H ⁺, and hydrolyze cellular phospholipids to disrupt the cellular integrity of microorganisms, thus exhibiting antibacterial activity. Magnesium hydroxide, 99%(KT) downregulates the generation of inflammatory macrophages to alleviate inflammatory responses. Magnesium hydroxide, 99%(KT) can be used in research related to acid peptic diseases and chronic wound infections .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0481

Roburic acid 1 Publications Verification	Triterpenes Structural Classification Gentiana macrophylla Pall. Classification of Application Fields Terpenoids Gentianaceae Plants Inflammation/Immunology Disease Research Fields Source Classification	COX TNF Receptor NO Synthase Interleukin Related NF-κB Apoptosis p38 MAPK JNK ERK Keap1-Nrf2 RANKL/RANK
Roburic acid acts as an anti-inflammatory, anti-tumor and osteoclastogenesis inhibitor, with a K_i of 7.066 μM against human TNF, an IC₅₀ of 9 μM against human *COX-2, and an IC₅₀* of 5 μM against ovine *COX-1. Roburic acid reduces the production of inflammatory mediators such as NO and IL-6* in macrophages by inhibiting the NF-κB and MAPK (p38/JNK) pathways. By competitively inhibiting the TNF-TNF-R1 interaction, Roburic acid blocks the downstream NF-κB signaling pathway, thereby inducing cell cycle arrest and apoptosis in cancer cells. Roburic acid specifically inhibits osteoclastogenesis and bone resorption by suppressing the RANKL/TRAF6/NF-κB/NFATc1 axis. Roburic acid can be used in research related to osteolytic diseases such as osteoporosis, colorectal cancer and inflammatory diseases .

HY-W012817

Methylhydroquinone	Structural Classification Natural Products Microorganisms Classification of Application Fields Other Diseases Disease Research Fields Source Classification	Environmental Pollutants COX
Methylhydroquinone is an orally active *COX* inhibitor with IC₅₀s of 480.7 μM and 52.2 μM for ovine COX-1 and human recombinant COX-2, respectively. Methylhydroquinone has potential DNA damaging effects: 1) inhibiting COX-1 to reduce prostaglandin synthesis and exert anti-inflammatory activity; 2) inducing DNA single-strand breaks. Methylhydroquinone exerts its effects by competitively binding to the active sites of COX-1 (such as Tyr385, Met522) and non-covalent interactions .

HY-N10009

Cudraflavone B	Brosimopsis oblongifolia Phenols Polyphenols Plants Moraceae Source Classification	NF-κB TNF Receptor COX ERK p38 MAPK Sirtuin
Cudraflavone B is a prenylated flavonoid with anti-inflammatory and anti-tumor properties. Cudraflavone B is also a dual inhibitor of *COX-1* and *COX-2. Cudraflavone B blocks the translocation of nuclear factor κB* (NF-κB) from the cytoplasm to the nucleus in macrophages. Thus, Cudraflavone B inhibits tumor necrosis factor α (TNFα) gene expression and secretion. Cudraflavone B also triggers the mitochondrial apoptotic pathway, activates NF-κB, the MAPK p38, and ERK, and induced the expression of SIRT1. Thus Cudraflavone B inhibits the growth of human oral squamous cell carcinoma cells .

HY-W012817R

Methylhydroquinone (Standard)	Natural Products Microorganisms Source Classification	COX Reference Standards
Methylhydroquinone (Standard) is the analytical standard of Methylhydroquinone. This product is intended for research and analytical applications. Methylhydroquinone is an orally active COX inhibitor with IC50s of 480.7 μM and 52.2 μM for ovine COX-1 and human recombinant COX-2, respectively. Methylhydroquinone has potential DNA damaging effects: 1) inhibiting COX-1 to reduce prostaglandin synthesis and exert anti-inflammatory activity; 2) inducing DNA single-strand breaks. Methylhydroquinone exerts its effects by competitively binding to the active sites of COX-1 (such as Tyr385, Met522) and non-covalent interactions[1][2].

HY-N0481R

Roburic acid (Standard)	Triterpenes Structural Classification Gentiana macrophylla Pall. Terpenoids Gentianaceae Plants Source Classification	Reference Standards COX TNF Receptor NO Synthase Interleukin Related NF-κB Apoptosis p38 MAPK JNK ERK Keap1-Nrf2 RANKL/RANK
Roburic acid (Standard) is the analytical standard of Roburic acid. This product is intended for research and analytical applications. Roburic acid acts as an anti-inflammatory, anti-tumor and osteoclastogenesis inhibitor, with a K_i of 7.066 μM against human TNF, an IC₅₀ of 9 μM against human *COX-2, and an IC₅₀* of 5 μM against ovine *COX-1. Roburic acid reduces the production of inflammatory mediators such as NO and IL-6* in macrophages by inhibiting the NF-κB and MAPK (p38/JNK) pathways. By competitively inhibiting the TNF-TNF-R1 interaction, Roburic acid blocks the downstream NF-κB signaling pathway, thereby inducing cell cycle arrest and apoptosis in cancer cells. Roburic acid specifically inhibits osteoclastogenesis and bone resorption by suppressing the RANKL/TRAF6/NF-κB/NFATc1 axis. Roburic acid can be used in research related to osteolytic diseases such as osteoporosis, colorectal cancer and inflammatory diseases.

Cat. No.	Product Name	Chemical Structure

HY-15036S

Diclofenac-d4
Diclofenac-d₄ is the deuterium labeled Diclofenac. Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC₅₀s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .

HY-15036S1

Diclofenac-13C6
Diclofenac- ¹³C₆ is the ¹³C₆ labeled Diclofenac. Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade.

HY-15321S

Etoricoxib-d4 1 Publications Verification
Etoricoxib-d₄ (MK-0663-d₄) is a deuterium labeled Etoricoxib. Etoricoxib is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.

HY-15037S2

Diclofenac-13C6 sodium

Diclofenac- ¹³C₆ (Sodium) is the ¹³C₆ labeled Diclofenac (Sodium). Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade.

HY-15037S1

Diclofenac-d4 sodium

Diclofenac-d₄ (sodium) is the deuterium labeled Diclofenac sodium. Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC₅₀s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .

HY-B0227S

Ketoprofen-d3
Ketoprofen-d₃ is the deuterium labeled Ketoprofen. Ketoprofen (RP-19583) is a non-steroidal antiinflammatory agent, acting as a potent inhibitor of COX, with IC₅₀s of 2 nM and 26 nM for COX-1 and COX-2 in human blood monocytes, respectively .

HY-14397S

Indomethacin-d4
Indomethacin-d₄ (Indometacin-d₄) is a deuterium labeled Indomethacin. Indomethacin is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2, with IC₅₀s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells . Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes .

HY-14397S1

Indomethacin-d4 Methyl Ester
Indomethacin-d₄ Methyl Ester is the deuterium labeled Indomethacin. Indomethacin (Indometacin) is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2, with IC₅₀s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells . Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes .

HY-B0253S

Piroxicam-d3
Piroxicam-d₃ (CP-16171-d₃) is deuterium labeled Piroxicam. Piroxicam is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC₅₀s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively .

HY-15321S2

Etoricoxib-d3
Etoricoxib-d₃ is the deuterium labeled Etoricoxib . Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC₅₀s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood .

HY-17372S

Rofecoxib-d5
Rofecoxib-d₅ is the deuterium labeled Rofecoxib. Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC₅₀s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC₅₀ > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells) .

HY-B0808S1

Oxaprozin-d5
Oxaprozin-d₅ is deuterium labeled Oxaprozin. Oxaprozin is an inhibitor of both COX-1 and COX-2 with IC50s of 2.2 μM and 36 μM for human platelet COX-1 and IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB.

HY-15037S

Diclofenac-13C6 sodium heminonahydrate

Diclofenac- ¹³C₆ (sodium heminonahydrate) is the ¹³C-labeled Diclofenac Sodium. Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC₅₀s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .

HY-B0253S1

Piroxicam-d4
Piroxicam-d₄ is the deuterium labeled Piroxicam. Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively.

HY-B0227S1

Ketoprofen-d4
Ketoprofen-d₄ is the deuterium labeled Ketoprofen. Ketoprofen (RP-19583) is a non-steroidal antiinflammatory agent, acting as a potent inhibitor of COX, with IC₅₀s of 2 nM and 26 nM for COX-1 and COX-2 in human blood monocytes, respectively .

HY-B1799S

Tolmetin-d3
Tolmetin-d₃ is the deuterium labeled Tolmetin. Tolmetin is an orally active and potent COX inhibitor with IC₅₀s of 0.35 μM and 0.82 μM human COX-1 and COX-2, respectively. Tolmetin is a non-steroidal anti-inflammatory drug (NSAID) .

HY-B0227S2

Ketoprofen-13C,d3
Ketoprofen- ¹³C,d₃ is the ¹³C- and deuterium labeled Ketoprofen. Ketoprofen (RP-19583) is a non-steroidal antiinflammatory agent, acting as a potent inhibitor of COX, with IC₅₀s of 2 nM and 26 nM for COX-1 and COX-2 in human blood monocytes, respectively .

HY-15321S1

Etoricoxib-13C,d3
Etoricoxib- ¹³C,d₃ is the ¹³C- and deuterium labeled Etoricoxib. Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.

HY-W753345

2,6-Dichlorodiphenylamine-13C6

2,6-Dichlorodiphenylamine- ¹³C₆ (2,6-Dichloro-N-phenylaniline- ¹³C₆) is the ¹³C-labeled 2,6-Dichlorodiphenylamine (HY-W012126). 2,6-Dichlorodiphenylamine is an analogue of Diclofenac Sodium (HY-15037) and has anti-Candida albicans activity. Diclofenac Sodium is a potent and nonselective anti-inflammatory agent, acts as a?COX?inhibitor, with?IC₅₀s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells.

HY-W709448

Oxaprozin-d10

Oxaprozin-d₁₀ (Oxaprozinum-d₁₀; Wy21743-d₁₀) is the deuterium labeled Oxaprozin (HY-B0808). Oxaprozin is an orally active and potent COX inhibitor, with IC₅₀ values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. Oxaprozin induces cell apoptosis. Oxaprozin shows anti-inflammatory activity. Oxaprozin-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86965

	MTCO1 Antibody (YA6658) COI antibody; COX I antibody; COX1 antibody; COX1_human antibody; COXI antibody; Cytochrome c oxidase polypeptide I antibody; Cytochrome c oxidase subunit 1 antibody; Cytochrome C Oxidase subunit I antibody; Mitochondrially encoded cytochrome c oxidase I antibody; MT CO1 antibody; COI antibody; COX I antibody; COX1 antibody; COX1_human antibody; COXI antibody; Cytochrome c oxidase polypeptide I antibody; Cytochrome c oxidase subunit 1 antibody; Cytochrome C Oxidase subunit I antibody; Mitochondrially encoded cytochrome c oxidase I antibody; MT CO1 antibody; MT-CO1 antibody; MTCO 1 antibody; MTCO1 antibody;	WB, ICC/IF, IHC-P, FC, IF-Tissue	Human, Mouse, Rat
	MTCO1 Antibody (YA6658) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MTCO1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

human COX-1

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Natural
Products